Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02535533 · ClinicalTrials.gov registry record · Phase 1
SLM + Axitinib for Clear Cell RCC
A Phase 1 study of Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC), sponsored by Mohammed Milhem.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT02535533: Completed Phase 1 study of Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC), sponsored by Mohammed Milhem.
NCT02535533 is a Phase 1 study of Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC) that has completed, run by Mohammed Milhem. The registered enrollment target is 46 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (23% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02535533, a Phase 1 study of Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC), has completed, sponsored by Mohammed Milhem.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the side effects and best dose of L-selenomethionine when given together with axitinib in treating patients with clear cell renal cell carcinoma that has spread from the primary site (place where it started) to other places in the body and usually cannot be cured or controlled with treatment (advanced metastatic). L-selenomethionine may stop the growth of tumor cells by blocking the growth of new blood vessels necessary for tumor growth. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving L-selenomethionine together with axitinib may be a better treatment for advanced metastatic clear cell renal cell carcinoma.
Primary Outcome
The AEs will be summarized and classified by body system and by treatment group. The type, incidence, severity, and causality of each AE, the duration of the event, and any required treatment interventions will be tabulated.
Conditions Studied
Interventions
- DRUG Axitinib
- DRUG Selenomethionine (SLM)
Study Locations (1)
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2016-01 |
| Est. Completion | 2025-04-04 |
| Phase | Phase 1 |
What the finished NCT02535533 record still lists
NCT02535533 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (23% lower).
The record links to 1 condition, with Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC) appearing as the primary indexed condition, and to 2 interventions - of which Axitinib is the first listed.
NCT02535533 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT02535533 about?
NCT02535533 is a clinical study titled "SLM + Axitinib for Clear Cell RCC". This phase I trial studies the side effects and best dose of L-selenomethionine when given together with axitinib in treating patients with clear cell renal cell carcinoma that has spread from the primary site (place where it started) to other places in the body and usually cannot be cured or contro...
What is the current status of trial NCT02535533?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2016-01. Estimated completion is 2025-04-04.
What conditions does trial NCT02535533 study?
This clinical trial studies the following conditions: Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC).
What interventions are being tested in trial NCT02535533?
The interventions under investigation include: Axitinib (DRUG), Selenomethionine (SLM) (DRUG).
Who is sponsoring clinical trial NCT02535533?
This trial is sponsored by Mohammed Milhem, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02535533 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02535533's enrollment target sits among peer trials
46 1058th of 2000 higher than 935 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia